Patient 27 (esthesioneuroblastoma with NTRK3 amplification) was treated with the TKI crizotinib which was discontinued due to side effects (see below) after 6 months of therapy, although follow-up MRI showed a SD. The gene discussed is NTRK3; the disease is olfactory neuroblastoma.